Defect in MAPK signaling as a cause for monogenic obesity caused by inactivating mutations in the melanocortin-4 receptor gene

International Journal of Biological Sciences

Volumn 10, Issue 10, 2014, Pages 1128-1137

  He, Shan ^a,b   Tao, Ya Xiong ^a  

^a AUBURN UNIVERSITY   (United States)

^b HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

Biased signaling; Extracellular signal regulated kinases 1 and 2 signaling; Melanocortin 4 receptor; Naturally occurring mutation

Indexed keywords

MELANOCORTIN 4 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

CHEMICAL STRUCTURE; GENETICS; HEK293 CELL LINE; HUMAN; IMAGE PROCESSING; IMMUNOBLOTTING; LUMINESCENCE; METABOLISM; MUTATION; OBESITY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

HEK293 CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOBLOTTING; LUMINESCENT MEASUREMENTS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MODELS, MOLECULAR; MUTATION; OBESITY; PHOSPHORYLATION; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 84907866005     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.10359     Document Type: Article

References (66)

1. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997; 88: 131-41.
2. Cone RD. Anatomy and regulation of the central melanocortin system. Nat Neurosci. 2005; 8: 571-8.
3. Tao YX. The melanocortin-4 receptor: Physiology, pharmacology, and pathophysiology. Endocr Rev. 2010; 31: 506-43.
4. Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003; 348: 1085-95.
5. Tao YX. Mutations in melanocortin-4 receptor and human obesity. Prog Mol Biol Transl Sci. 2009; 88: 173-204.
6. Hinney A, Volckmar AL, Knoll N. Melanocortin-4 receptor in energy homeostasis and obesity pathogenesis. Prog Mol Biol Transl Sci. 2013; 114: 147-91. doi:10.1016/B978-0-12-386933-3.00005-4.
7. Tao YX, Segaloff DL. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metab. 2005; 90: 5632-8.
8. Gantz I, Miwa H, Konda Y, Shimoto Y, Tashiro T, Watson SJ, et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem. 1993; 268: 15174-9.
9. Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol. 1994; 8: 1298-308.
10. Tao YX. Constitutive activity in melanocortin-4 receptor: biased signaling of inverse agonists. Adv Pharmacol. 2014; 70: 135-54.
11. Breit A, Büch TR, Boekhoff I, Solinski HJ, Damm E, Gudermann T. Alternative G protein coupling and biased agonism: new insights into melanocortin-4 receptor signalling. Mol Cell Endocrinol. 2011; 331: 232-40.
12. Büch TR, Heling D, Damm E, Gudermann T, Breit A. Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist. J Biol Chem. 2009; 284: 26411-20.
13. Chai B, Li JY, Zhang W, Newman E, Ammori J, Mulholland MW. Melanocortin-4 receptor-mediated inhibition of apoptosis in immortalized hypothalamic neurons via mitogen-activated protein kinase. Peptides. 2006; 27: 2846-57.
14. Daniels D, Patten CS, Roth JD, Yee DK, Fluharty SJ. Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus. Brain Res. 2003; 986: 1-11.
15. Vongs A, Lynn NM, Rosenblum CI. Activation of MAP kinase by MC4-R through PI3 kinase. Regul Pept. 2004; 120: 113-8.
16. Mo XL, Tao YX. Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors. Biochim Biophys Acta. 2013; 1832: 1939-48.
17. Sutton GM, Duos B, Patterson LM, Berthoud HR. Melanocortinergic modulation of cholecystokinin-induced suppression of feeding through extracellular signal-regulated kinase signaling in rat solitary nucleus. Endocrinology. 2005; 146: 3739-47.
18. Patten CS, Daniels D, Suzuki A, Fluharty SJ, Yee DK. Structural and signaling requirements of the human melanocortin 4 receptor for MAP kinase activation. Regul Pept. 2007; 142: 111-22.
19. Huang H, Tao YX. Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor. J Mol Endocrinol. 2012; 49: 237-48.
20. Mo XL, Yang R, Tao YX. Functions of transmembrane domain 3 of human melanocortin-4 receptor. J Mol Endocrinol. 2012; 49: 221-35.
21. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci. 1995; 16: 232-8.
22. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 2001; 15: 598-611.
23. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther. 2007; 320: 1-13.
24. Rajagopal S, Rajagopal K, Lefkowitz RJ. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat Rev Drug Discov. 2010; 9: 373-86.
25. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ. Molecular mechanism of β-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol. 2012; 52: 179-97.
26. Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 2014; 35: 308-16.
27. Liu JJ, Horst R, Katritch V, Stevens RC, Wuthrich K. Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science. 2012; 335: 1106-10.
28. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013; 340: 615-9.
29. Fenalti G, Giguere PM, Katritch V, Huang XP, Thompson AA, Cherezov V, et al. Molecular control of δ-opioid receptor signalling. Nature. 2014; 506: 191-6.
30. Shukla AK, Westfield GH, Xiao K, Reis RI, Huang LY, Tripathi-Shukla P, et al. Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature. 2014; 512: 218-22.
31. Lefkowitz RJ. A brief history of G-protein coupled receptors (Nobel Lecture). Angew Chem Int Ed Engl. 2013; 52: 6366-78.
32. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci U S A. 2003; 100: 10782-7.
33. Grasberger H, Van Sande J, Hag-Dahood Mahameed A, Tenenbaum-Rakover Y, Refetoff S. A familial thyrotropin (TSH) receptor mutation provides in vivo evidence that the inositol phosphates/Ca2+ cascade mediates TSH action on thyroid hormone synthesis. J Clin Endocrinol Metab. 2007; 92: 2816-20.
34. Herraiz C, Jimenez-Cervantes C, Zanna P, Garcia-Borron JC. Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways. FEBS Lett. 2009; 583: 3269-74.
35. Leach K, Wen A, Davey AE, Sexton PM, Conigrave AD, Christopoulos A. Identification of molecular phenotypes and biased signaling induced by naturally occurring mutations of the human calcium-sensing receptor. Endocrinology. 2012; 153: 4304-16.
36. Sbai O, Monnier C, Dode C, Pin JP, Hardelin JP, Rondard P. Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations. FASEB J. 2014; 28: 3734-44.
37. Tao YX, Segaloff DL. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology. 2003; 144: 4544-51.
38. Donohoue PA, Tao YX, Collins M, Yeo GSH, O'Rahilly S, Segaloff DL. Deletion of codons 88-92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female. J Clin Endocrinol Metab. 2003; 88: 5841-5.
39. Rong R, Tao YX, Cheung BM, Xu A, Cheung GC, Lam KS. Identification and functional characterization of three novel human melanocortin-4 receptor gene variants in an obese Chinese population. Clin Endocrinol. 2006; 65: 198-205.
40. Fan ZC, Tao YX. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med. 2009; 13: 3268-82.
41. Roth CL, Ludwig M, Woelfle J, Fan ZC, Brumm H, Biebermann H, et al. A novel melanocortin-4 receptor gene mutation in a female patient with severe childhood obesity. Endocrine. 2009; 36: 52-9.
42. Wang ZQ, Tao YX. Functional studies on twenty novel naturally occurring melanocortin-4 receptor mutations. Biochim Biophys Acta. 2011; 1812: 1190-9.
43. Hohenadel MG, Thearle MS, Grice BA, Huang H, Dai MH, Tao YX, et al. Brain-derived neurotrophic factor in human subjects with function-altering melanocortin-4 receptor variants. Int J Obes (Lond). 2014; 38: 1068-74.
44. Yeo GS, Lank EJ, Farooqi IS, Keogh J, Challis BG, O'Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet. 2003; 12: 561-74.
45. Alfieri A, Pasanisi F, Salzano S, Esposito L, Martone D, Tafuri D, et al. Functional analysis of melanocortin-4-receptor mutants identified in severely obese subjects living in Southern Italy. Gene. 2010; 457: 35-41.
46. Moore BS, Mirshahi UL, Yost EA, Stepanchick AN, Bedrin MD, Styer AM, et al. Long-term weight-loss in gastric bypass patients carrying melanocortin 4 receptor variants. PLoS One. 2014; 9: e93629.
47. Biebermann H, Krude H, Elsner A, Chubanov V, Gudermann T, Gruters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes. 2003; 52: 2984-8.
48. Tarnow P, Rediger A, Brumm H, Ambrugger P, Rettenbacher E, Widhalm K, et al. A heterozygous mutation in the third transmembrane domain causes a dominant-negative effect on signaling capability of the MC4R. Obes Facts. 2008; 1: 155-62.
49. Tao YX. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol. 2005; 239: 1-14.
50. Tao YX. Inactivating mutations of G protein-coupled receptors and diseases: Structure-function insights and therapeutic implications. Pharmacol Ther. 2006; 111: 949-73.
51. Tao YX, Conn PM. Chaperoning G protein-coupled receptors: From cell biology to therapeutics. Endocr Rev. 2014; 35: 602-47.
52. Rene P, Le Gouill C, Pogozheva ID, Lee G, Mosberg HI, Farooqi IS, et al. Pharmacological chaperones restore function to MC4R mutants responsible for severe early-onset obesity. J Pharmacol Exp Ther. 2010; 335: 520-32.
53. Tranchant T, Durand G, Gauthier C, Crepieux P, Ulloa-Aguirre A, Royere D, et al. Preferential β-arrestin signalling at low receptor density revealed by functional characterization of the human FSH receptor A189 V mutation. Mol Cell Endocrinol. 2011; 331: 109-18.
54. Tao YX, Huang H, Wang ZQ, Yang F, Williams JN, Nikiforovich GV. Constitutive activity of neural melanocortin receptors. Methods Enzymol. 2010; 484: 267-79.
55. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, Conklin BR, et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest. 2004; 114: 1158-64.
56. Hinney A, Hohmann S, Geller F, Vogel C, Hess C, Wermter AK, et al. Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab. 2003; 88: 4258-67.
57. Benned-Jensen T, Mokrosinski J, Rosenkilde MM. The E92K melanocortin 1 receptor mutant induces cAMP production and arrestin recruitment but not ERK activity indicating biased constitutive signaling. PLoS One. 2011; 6: e24644.
58. Huang H, Tao YX. A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants. Int J Biol Sci. 2014; 10: 817-24.
59. Tao YX, Huang H. Ipsen 5i is a novel potent pharmacoperone for intracellularly retained melanocortin-4 receptor mutants. Front Endocrinol (Lausanne). 2014; 5: 131.
60. Nijenhuis WA, Garner KM, VanRozen RJ, Adan RA. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem. 2003; 278: 22939-45.
61. Lubrano-Berthelier C, Durand E, Dubern B, Shapiro A, Dazin P, Weill J, et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet. 2003; 12: 145-53.
62. Kobayashi H, Ogawa Y, Shintani M, Ebihara K, Shimodahira M, Iwakura T, et al. A novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity. Diabetes. 2002; 51: 243-6.
63. Piechowski CL, Rediger A, Lagemann C, Muhlhaus J, Muller A, Pratzka J, et al. Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2. J Mol Endocrinol. 2013; 51: 109-18.
64. Xiang Z, Proneth B, Dirain ML, Litherland SA, Haskell-Luevano C. Pharmacological characterization of 30 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists, synthetic agonists, and the endogenous agouti-related protein antagonist. Biochemistry. 2010; 49: 4583-600.
65. Yang JJ, Tang SS, Hu C, Zhang R, Song ZC, Wang B, et al. Screening for melanocortin 4 receptor mutations in Chinese extremely obese individuals. Biomed Environ Sci. 2013; 26: 611-3.
66. Lubrano-Berthelier C, Dubern B, Lacorte JM, Picard F, Shapiro A, Zhang S, et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab. 2006; 91: 1811-8.